Category: fda

Setting the Record Straight on the FDA’s Authority Over Drug Ads

KFF Health News gives readers a chance to comment on a recent batch of stories.

The FDA Calls Them ‘Recalls,’ Yet the Targeted Medical Devices Often Remain in Use

With medical devices, recalls are not always what they seem. In some recalls, including some of the most serious, the FDA and the manufacturers let doctors and hospitals continue to use the devices.

Inside Project 2025: Former Trump Official Outlines Hard Right Turn Against Abortion

Former President Donald Trump has distanced himself from a Heritage Foundation document that outlines positions on abortion and a range of other social issues. But Democrats view it as a window into the far right’s to-do list and a clear opening for political attack.

The CDC’s Test for Bird Flu Works, but It Has Issues

The Centers for Disease Control and Prevention promises better tests are in the works, but the episode points to vulnerabilities in the country’s defense against emerging outbreaks.

Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs

Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.

From Dr. Oz to Heart Valves: A Tiny Device Charted a Contentious Path Through the FDA

The story of MitraClip, a device Dr. Oz helped invent to treat faulty heart valves, is a cautionary tale about the science, business, and regulation of medical technology.

KFF Health News’ ‘What the Health?’: SCOTUS Term Wraps With a Bang

The Supreme Court has issued its final opinions for the 2023-24 term, including decisions affecting abortion access, the opioid epidemic, and how the federal government functions. In this special episode, Sarah Somers , legal director of the National Health Law Program, joins KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss how the justices disposed of the term’s health-related cases and what those decisions could mean going forward.

The Supreme Court Just Limited Federal Power. Health Care Is Feeling the Shockwaves.

A Supreme Court ruling restricting federal power will likely have seismic ramifications for health policy. A flood of litigation — with plaintiffs like small businesses, drugmakers, and hospitals challenging regulations they say are too expensive or burdensome and not authorized by law — could leave the country with a patchwork of disparate health regulations.

KFF Health News’ ‘What the Health?’: SCOTUS Ruling Strips Power From Federal Health Agencies

In what will certainly be remembered as a landmark decision, the Supreme Court has overruled a 40-year-old precedent that gave federal agencies, rather than judges, the power to interpret ambiguous laws passed by Congress. Administrative experts say the decision will dramatically change the way key health agencies do business. Also, the court decided not to decide whether a federal law requiring hospitals to provide emergency care overrides Idaho’s near-total ban on abortion. Alice Miranda Ollstein of Politico, Victoria Knight of Axios, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.

KFF Health News’ ‘What the Health?’: SCOTUS Rejects Abortion Pill Challenge — For Now 

The Supreme Court has dismissed a challenge to the FDA’s approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of KFF Health News, and Emmarie Huetteman of KFF Health News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF president and CEO Drew Altman about KFF’s new “Health Policy 101” primer.